NCT04654455

Prospective Study Evaluating Dry Eye in Patients Operated on for Ametropia by LASIK Surgery and Treated With REPADROP

Name: Clinical Trial NCT04654455
Creator: Hospices Civils de Lyon
Keywords: Ametropia, Describe the evolution of dry eye between 1 month and 3 months post-LASIK, other, clinical trial, France

Hospices Civils de Lyon·ClinicalTrials.gov·otherCompleted

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Ametropia
Drug/Device/Intervention: Describe the evolution of dry eye between 1 month and 3 months post-LASIK
Study type: Observational
Intervention type: other

Sponsor & location

Primary sponsor: Hospices Civils de Lyon
Location: Lyon, France

Timeline & enrollment

Phase: N/A
Start date: Mar 09, 2021
End date: Nov 02, 2021
Enrollment: 10 participants

Primary outcome

Variation in OSDI (Ocular Surface Disease Index) score

Summary

LASIK is a refractive surgery technique widely used in France. Postoperatively, the classic treatment after LASIK consists of instilling drops to reduce dry eyes. REPADROP® is an innovative eye drops stimulating corneal innervation. To date no study has quantified the improvement in dry eye syndrome and thus the quality of life of patients using REPADROP®.

ICD-10 classifications

Amblyopia ex anopsiaAmoebiasisAmoebiasis, unspecifiedMyoclonusOesophagitis

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT04654455
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT04654455 through Pure Global AI's free database. This phase not specified trial is sponsored by Hospices Civils de Lyon and is currently Completed. The study focuses on Ametropia. Target enrollment is 10 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.